PathogenDX

Tucson, United States Founded: 2014 • Age: 12 yrs
Provider of DNA-based pathogen testing kits
Request Access

About PathogenDX

PathogenDX is a company based in Tucson (United States) founded in 2014 by Eric Lachance and Michael Hogan.. PathogenDX has raised $11.58 million across 5 funding rounds from investors including NIH, HHS and Entourage Effect Capital. The company has 31 employees as of December 31, 2021. PathogenDX offers products and services including D3 Array™, Octa™ AutoPrep Station, and Sero X Assay. PathogenDX operates in a competitive market with competitors including Inflammatix, Agendia, GenomeDx Biosciences, Akonni and KromaTiD, among others.

  • Headquarter Tucson, United States
  • Employees 31 as on 31 Dec, 2021
  • Founders Eric Lachance, Michael Hogan
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Pathogendx, Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $11.58 M (USD)

    in 5 rounds

  • Latest Funding Round
  • Investors
    NIH

    & 7 more

  • Employee Count
    31

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of PathogenDX

PathogenDX offers a comprehensive portfolio of products and services, including D3 Array™, Octa™ AutoPrep Station, and Sero X Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Rapid multiplexed pathogen detection for clinical and food use

Automates lab workflows for cannabis pathogen testing

Detects Salmonella serotypes in food processing

People of PathogenDX
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 9
Employee Profiles
People
David Stolberg
Creative Director & Founder, RULE OF 3, Marketing Team
People
Milan Patel
Co-Founder & CEO
People
Michael Hogan
Co-Founder & Chief Scientific Officer
People
Benjamin Katchman
Vice President Of Product Development

Unlock access to complete

Board Members and Advisors
people
Sue Evans
Board Advisor, Clinical & Human Diagnostics
people
Neal Patel
Board Member
people
Paul Glyer
Board Advisor, Clinical & Human Diagnostics
people
Michael Dovbish
Board Advisor

Unlock access to complete

Funding Insights of PathogenDX

PathogenDX has successfully raised a total of $11.58M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round
  • First Round

    (19 Apr 2016)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2020 Amount Grant - PathogenDX Valuation

investors

NIH
Aug, 2020 Amount Grant - PathogenDX Valuation

investors

HHS
Sep, 2019 Amount Series B - PathogenDX Valuation Entourage Effect Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in PathogenDX

PathogenDX has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Entourage Effect Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment firm focused on cannabis industry growth and leadership.
Founded Year Domain Location
Investments are focused on the emerging global cannabis industry.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by PathogenDX

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - PathogenDX

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Pathogendx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of PathogenDX

PathogenDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, GenomeDx Biosciences, Akonni and KromaTiD, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of diagnostic solutions for systemic infections
domain founded_year HQ Location
Genomic diagnostic products for cancer treatment are provided.
domain founded_year HQ Location
Genomic tests for urologic cancers are developed and commercialized.
domain founded_year HQ Location
Molecular diagnostics for complex infections are developed by Akonni.
domain founded_year HQ Location
Molecular and genetic tests for detecting disease-causing mutations are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Pathogendx

Frequently Asked Questions about PathogenDX

When was PathogenDX founded?

PathogenDX was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is PathogenDX located?

PathogenDX is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.

Is PathogenDX a funded company?

PathogenDX is a funded company, having raised a total of $11.58M across 5 funding rounds to date. The company's 1st funding round was a Series B of $7.5M, raised on Apr 19, 2016.

How many employees does PathogenDX have?

As of Dec 31, 2021, the latest employee count at PathogenDX is 31.

What does PathogenDX do?

PathogenDX was founded in 2014 and is based in Tucson, United States. DNA-based testing kits for pathogen detection are offered by the company to the botanicals, food, and agriculture industries. Operations center on microbial testing services, including those for cannabis and botanical applications, with a focus on supporting safety and quality assessments in these sectors.

Who are the top competitors of PathogenDX?

PathogenDX's top competitors include Inflammatix, Agendia and KromaTiD.

What products or services does PathogenDX offer?

PathogenDX offers D3 Array™, Octa™ AutoPrep Station, and Sero X Assay.

Who are PathogenDX's investors?

PathogenDX has 8 investors. Key investors include NIH, HHS, Entourage Effect Capital, Altitude Investment Management, and Arcadian Investment Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available